Cara Therapeutics Company Profile (NASDAQ:CARA)

About Cara Therapeutics

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CARA
  • CUSIP:
Key Metrics:
  • Previous Close: $8.35
  • 50 Day Moving Average: $6.36
  • 200 Day Moving Average: $5.98
  • 52-Week Range: $4.26 - $18.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.94
  • P/E Growth: 0.00
  • Market Cap: $227.80M
  • Outstanding Shares: 27,282,000
  • Beta: 3
Profitability:
  • Return on Equity: -38.43%
  • Return on Assets: -36.03%
Debt:
  • Current Ratio: 10.92%
  • Quick Ratio: 10.92%
Additional Links:
Companies Related to Cara Therapeutics:

Analyst Ratings

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.71 (160.05% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Piper Jaffray Cos.Reiterated RatingOverweight$16.00View Rating Details
9/15/2016Cantor FitzgeraldSet Price TargetBuy$24.00View Rating Details
8/7/2016Needham & Company LLCLower Price TargetBuy$27.00 -> $23.00View Rating Details
8/5/2016Stifel NicolausLower Price TargetBuy$25.00 -> $24.00View Rating Details
5/6/2016Canaccord GenuityReiterated RatingBuy$30.00View Rating Details
3/12/2016Janney Montgomery ScottReiterated RatingBuy$23.00 -> $18.00View Rating Details
2/29/2016LaidlawLower Price TargetBuy$30.00 -> $17.00View Rating Details
3/3/2015MLV & Co.Initiated CoverageBuy$26.00View Rating Details
12/9/2014Summer StreetInitiated CoverageBuy$20.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Cara Therapeutics (NASDAQ:CARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)ViewListenView Earnings Details
5/12/2015Q415($0.27)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.30)($0.18)$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
Current Year EPS Consensus Estimate: $-1.81 EPS
Next Year EPS Consensus Estimate: $-1.69 EPS

Dividends

Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cara Therapeutics (NASDAQ:CARA)
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 48.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cara Therapeutics (NASDAQ:CARA)
DateHeadline
News IconPruritus Global Pipeline Review Research H2 2016 (NASDAQ:CARA)
www.khq.com - September 30 at 8:31 AM
News IconBiotech Stocks To Put On Your Watch List: Cara Therapeutics Inc ... - The Voice Registrar (NASDAQ:CARA)
voiceregistrar.com - September 29 at 3:36 PM
News IconActive biotech company shares in the news: Cara Therapeutics Inc ... - The Voice Registrar (NASDAQ:CARA)
voiceregistrar.com - September 29 at 3:36 PM
News IconOverbuying Stock in the Spotlight: Cara Therapeutics Inc (NASDAQ:CARA) - Post Registrar (NASDAQ:CARA)
postregistrar.com - September 29 at 3:36 PM
globenewswire.com logoCara Therapeutics to Host Industry Symposium at the Orthopaedic ... - GlobeNewswire (press release) (NASDAQ:CARA)
globenewswire.com - September 29 at 3:36 PM
finance.yahoo.com logoCara Therapeutics to Host Industry Symposium at the Orthopaedic Trauma Association 2016 Annual Meeting (NASDAQ:CARA)
finance.yahoo.com - September 29 at 8:57 AM
News IconLatest report on diabetic gastroparesis pipeline market analysis H2 2016 made available by top research firm (NASDAQ:CARA)
www.whatech.com - September 28 at 3:56 PM
News IconArray Biopharma Inc (NASDAQ:ARRY), Cara Therapeutics Inc (NASDAQ:CARA) Gave Huge profit To Members At Traders Insights (NASDAQ:CARA)
www.marketnewscall.com - September 28 at 3:56 PM
News IconCara Therapeutics Inc (NASDAQ:CARA) Continues Volume-backed Uptrend - Scibility Media (NASDAQ:CARA)
scibilitymedia.com - September 28 at 8:50 AM
News IconPay Close Attention To These Analyst Ratings Atwood Oceanics, Inc ... - The Voice Registrar (NASDAQ:CARA)
voiceregistrar.com - September 27 at 4:01 PM
News IconTime To Put On The Watch List? - Cara Therapeutics Inc. (NASDAQ:CARA), Conatus Pharmaceuticals Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:CARA)
voiceregistrar.com - September 27 at 4:01 PM
capitalcube.com logoETF’s with exposure to CARA Therapeutics, Inc. : September 27, 2016 (NASDAQ:CARA)
www.capitalcube.com - September 27 at 4:01 PM
News IconHot Biotech Stocks Recap: Cara Therapeutics Inc. (NASDAQ:CARA), Illumina Inc. (NASDAQ:ILMN) - The Voice Registrar (NASDAQ:CARA)
voiceregistrar.com - September 23 at 3:30 PM
News IconEnterisBioPharma's Congratulates Cara Therapeutics Inc (NASDAQ:CARA) On Successful Phase II Clinical Trial - Scibility Media (NASDAQ:CARA)
scibilitymedia.com - September 23 at 3:30 PM
News IconPruritus Therapeutics Market: Segments, Opportunity, Growth and Forecast By End-use Industry 2015-2020 (NASDAQ:CARA)
qwtjlive.com - September 22 at 4:14 PM
News IconActive News in Retreated Reviews- Mast Therapeutics, Inc. (NYSE ... - Seneca Globe (NASDAQ:CARA)
www.senecaglobe.com - September 21 at 8:04 AM
News IconXerox Corp (NYSE:XRX) & Cara Therapeutics Inc (NASDAQ:CARA) UPDATE ON U.S STOCKS: 19 SEP 2016 - Money News (NASDAQ:CARA)
www.newsismoney.com - September 21 at 8:04 AM
News IconEnteris BioPharma's Feasibility to Licensing Partner, Cara Therapeutics, Advances ... (NASDAQ:CARA)
www.biomedreports.com - September 20 at 9:55 AM
finance.yahoo.com logoEnteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence™-Engineered … (NASDAQ:CARA)
finance.yahoo.com - September 20 at 9:55 AM
News IconIntraday Movers: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ... - NYSE Journal (press release) (NASDAQ:CARA)
stockznews.com - September 19 at 4:53 PM
finance.yahoo.com logoEnteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence™-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain (NASDAQ:CARA)
finance.yahoo.com - September 19 at 4:53 PM
4-traders.com logoCara Therapeutics : Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients (NASDAQ:CARA)
www.4-traders.com - September 17 at 3:59 PM
News IconCara Therapeutics Inc (NASDAQ:CARA): What We’re Looking For From The OA Trial (NASDAQ:CARA)
streetregister.com - September 17 at 3:59 PM
News IconCara Therapeutics Inc (NASDAQ:CARA): What We're Looking For ... - Street Register (NASDAQ:CARA)
streetregister.com - September 17 at 8:51 AM
News IconChoyce Peterson negotiates 24,000 s/f lease for Cara Therapeutics (NASDAQ:CARA)
cre.nerej.com - September 16 at 7:01 AM
streetinsider.com logoCara Therapeutics (CARA) Commences CR845 Phase 2b Enrollment - StreetInsider.com (NASDAQ:CARA)
www.streetinsider.com - September 15 at 12:35 PM
publicnow.com logoCara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients (NASDAQ:CARA)
www.publicnow.com - September 15 at 12:35 PM
seekingalpha.com logoCara Therapeutics: Major Upside Potential - Seeking Alpha (NASDAQ:CARA)
seekingalpha.com - September 14 at 4:04 PM
News IconShares in Focus: Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings & Targets Update - Frisco Fastball (NASDAQ:CARA)
friscofastball.com - September 9 at 3:59 PM
News Icon2 Sizzling Hot Biotechnology Stocks: Cara Therapeutics Inc. (CARA ... - National Daily Press (NASDAQ:CARA)
www.nationaldailypress.com - September 9 at 3:59 PM
News Icon2 Biotech Stocks News And Price Trends: Cara Therapeutics Inc. (NASDAQ:CARA), Agios Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:CARA)
voiceregistrar.com - September 9 at 3:59 PM
capitalcube.com logoETF’s with exposure to CARA Therapeutics, Inc. : September 9, 2016 (NASDAQ:CARA)
www.capitalcube.com - September 9 at 3:59 PM
News IconPlacing Cara Therapeutics, Inc. (NASDAQ:CARA) Shares Under the ... - Post News (NASDAQ:CARA)
www.kentuckypostnews.com - September 8 at 6:34 AM
News IconMy Watchlist for Thursday, September 08 (NASDAQ:CARA)
ac-investor.blogspot.com - September 7 at 9:08 PM
News IconPain management market – new discoveries and treatment options in abuse deterrent era published by leading research firm (NASDAQ:CARA)
www.whatech.com - September 7 at 9:44 AM
News IconPruritus Therapeutics Market: Size, Share, Dynamics and Trends by 2014 – 2020 (NASDAQ:CARA)
www.medgadget.com - September 6 at 3:58 PM
thestreet.com logoHere's Why Investors Should Steer Clear of Opioids (NASDAQ:CARA)
www.thestreet.com - September 6 at 3:58 PM
News Icon$CARA to Webcast Presentation (NASDAQ:CARA)
marijuanastocks.com - September 4 at 8:43 AM
nasdaq.com logoCara Therapeutics to Sponsor Symposium and Present Posters at ... - Nasdaq (NASDAQ:CARA)
www.nasdaq.com - September 3 at 8:44 AM
News IconCara Therapeutics to Webcast Presentation at 23rd Annual NewsMakers in the Biotech Industry Conference - EconoTimes (NASDAQ:CARA)
www.econotimes.com - September 2 at 8:51 AM
publicnow.com logoCara Therapeutics to Webcast Presentation at 23rd Annual NewsMakers in the Biotech Industry Conference (NASDAQ:CARA)
www.publicnow.com - September 2 at 8:51 AM
News Icon$CARA to Sponsor Symposium and Present Posters at PAINWeek (NASDAQ:CARA)
marijuanastocks.com - September 1 at 4:01 PM
News IconCara Therapeutics Inc (NASDAQ:CARA) Is A Cheap Buyout Target - Street Register (NASDAQ:CARA)
streetregister.com - September 1 at 12:32 PM
News IconMGT Capital Investments Inc. (NYSEMKT:MGT) Is About To Get Shareholder Approval To Shift up A Gear (NASDAQ:CARA)
streetregister.com - August 31 at 8:52 AM
News IconCara Therapeutics Inc (NASDAQ:CARA) Is A Cheap Buyout Target (NASDAQ:CARA)
streetregister.com - August 30 at 11:55 AM
investornewswire.com logoCan Shares Of Cara Therapeutics, Inc. (NASDAQ:CARA) Get To $24? - Investor Newswire (NASDAQ:CARA)
www.investornewswire.com - August 29 at 8:34 PM
capitalcube.com logoETF’s with exposure to CARA Therapeutics, Inc. : August 29, 2016 (NASDAQ:CARA)
www.capitalcube.com - August 29 at 3:27 PM
prnewswire.com logoDiversity of the Legal and Medical Marijuana Markets (NASDAQ:CARA)
www.prnewswire.com - August 24 at 12:18 PM
4-traders.com logoZynerba Pharmaceuticals : Diversity of the Legal and Medical Marijuana Markets (NASDAQ:CARA)
www.4-traders.com - August 24 at 12:18 PM
live-pr.com logoNewly released market study: Cara Therapeutics, Inc. (CARA) - Financial and Strategic SWOT Analysis Review (NASDAQ:CARA)
www.live-pr.com - August 24 at 12:18 PM

Social

Cara Therapeutics (NASDAQ:CARA) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff